AstraZeneca Secures Tariff Relief in Exchange for Lower Drug Prices, Manufacturing Expansion
AstraZeneca, a leading global pharmaceutical company, has reached an agreement with the U.S. government to lower drug prices for Medicaid beneficiaries and offer discounts to consumers, alongside a significant expansion of its manufacturing and research footprint within the country. The deal, unveiled during an Oval Office press conference, aims to bring the cost of prescription drugs in the U.S. more in line with prices paid in other developed nations.
The agreement marks the second such deal brokered by the Trump administration with a major drugmaker, following a similar arrangement with Pfizer. A central component of the plan is most-favored-nation pricing for drugs sold to Medicaid, effectively tying U.S. prices to the lowest rates available internationally.
As part of the commitment, AstraZeneca will provide discounts of up to 80% off list prices on direct sales to consumers, focusing on medications like Bevespi Aerosphere for chronic obstructive pulmonary disease (COPD) and Airsupra for asthma. According to a company statement, the initiative will bypass traditional health insurance channels, offering patients a direct pathway to lower costs. “In other words the lowest price anywhere in the world, that’s what we get,” a senior official stated during the press conference.
In return for these concessions, AstraZeneca will receive a three-year exemption from certain tariffs. The White House initially announced its plans for TrumpRx – a government website designed to facilitate direct-to-consumer drug sales – alongside the Pfizer deal on September 30th. The TrumpRx platform, expected to launch in 2026, will direct consumers to pharmaceutical companies’ websites to complete their purchases.
However, the potential impact of these deals remains uncertain. One analyst noted that Medicaid already benefits from some of the lowest drug prices available, and individuals with existing health insurance coverage may find lower costs through copays rather than direct purchases.
Beyond price reductions, AstraZeneca has pledged to significantly increase its investment in U.S. manufacturing and research. The company announced an additional $500 million investment in a new facility in Virginia, bringing the total investment to $4.5 billion. This builds upon a broader $50 billion commitment, announced in July, to expand facilities in California, Indiana, Maryland, Massachusetts, Texas, and Virginia.
“For all the pharmaceutical companies out there — we’re talking to all of you, pick up a shovel,” said Dr. Mehmet Oz, who leads the Centers for Medicare and Medicaid Services, urging other companies to follow suit. The Trump administration claims to have secured a total of $18 trillion in commitments to bring pharmaceutical manufacturing back to the U.S., though NPR was unable to independently verify this figure.
The administration’s push for lower drug prices began with an executive order in May and continued with letters sent to 17 pharmaceutical companies over the summer, encouraging voluntary price reductions. While the long-term effects of these initiatives are yet to be seen, the AstraZeneca deal represents a significant step in the administration’s efforts to reshape the pharmaceutical landscape and address concerns over drug affordability.
